Holen Sie sich die Stockscreener-App
1.82
0.55%
-0.00
Schlusskurs vom Vortag:
$1.82
Offen:
$1.83
24-Stunden-Volumen:
21,221
Relative Volume:
0.38
Marktkapitalisierung:
$646.81M
Einnahmen:
$863.66M
Nettoeinkommen (Verlust:
$-225.27M
KGV:
-2.8698
EPS:
-0.6342
Netto-Cashflow:
$-63.28M
1W Leistung:
-4.74%
1M Leistung:
-9.50%
6M Leistung:
-40.26%
1J Leistung:
-47.38%
1-Tages-Spanne:
$1.805
$1.83
1-Wochen-Bereich:
$1.80
$1.95
52-Wochen-Spanne:
$1.80
$4.27
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
1.82 | 646.81M | 863.66M | -225.27M | -63.28M | -0.6342 |
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.80 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.18 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.65 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.44 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2026-02-03 | Eingeleitet | Berenberg | Buy |
| 2025-04-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Evotec starts Phase 1 trial for JST-018 antibody therapy - grafa.com
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Evotec stock struggles after profit warning as Q2 2026 figures and guidance cuts weigh on sentiment - AD HOC NEWS
Evotec stock trades close to 52-week low as Q2 revenue declines - AD HOC NEWS
Evotec stock trades at a discount to recent analyst targets as Xetra shares retreat - AD HOC NEWS
Evotec stock trades well below analyst targets as selling pressure intensifies - Ad-hoc-news.de
Evotec stock faces earnings estimate cut as ADR trades below $2 - AD HOC NEWS
Evotec AG Earnings Call: Weak 2026, Pipeline Hopes - The Globe and Mail
Evotec signs AI drug discovery partnership with Odyssey - grafa.com
Evotec SE (EVO) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesPost-Earnings Reaction - vinanet.vn
Berenberg cuts Evotec on delayed pharma deals clouding revenue outlook - Investing.com
Berenberg cuts Evotec stock rating on guidance downgrade By Investing.com - Investing.com Nigeria
Berenberg cuts Evotec stock rating on guidance downgrade - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen cuts Evotec on customer delays clouding growth outlook By Investing.com - Investing.com Nigeria
TD Cowen cuts Evotec on customer delays clouding growth outlook - Investing.com
H.C. Wainwright cuts Evotec stock price target on revenue guidance reduction - Investing.com
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com Nigeria
Earnings call transcript: Evotec cuts 2026 outlook as Q2 revenue falls - Investing.com Nigeria
Evotec slumps 32% after H1 loss widens, annual outlook slashed - Investing.com
Evotec stock. Thin source set keeps the focus on business context. - Ad Hoc News
EVTA Forecast — Price Target — Prediction for 2027 - TradingView
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec - news.financial
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec - news.financial
Evotec consensus picture on Wall Street, shares trade as ADR on NASDAQ - Ad-hoc-news.de
Evotec launches J.TRAIN for biologics manufacturing - grafa.com
Evotec consensus picture on Nasdaq EVO, shares hover around 2.74 dollars - ad-hoc-news.de
A0QZ3J Forecast — Price Target — Prediction for 2027 - TradingView
Evotec SE Sponsored ADR Actuals & Estimates (NASDAQ:EVO) - TradingView
Evotec refines analyst expectations, shares trade under 5 euros on Xetra - AD HOC NEWS
Evotec shows weak June performance, analyst consensus points above current shares - AD HOC NEWS
Evotec Stockweekly review and sector comparison - Ad-hoc-news.de
Which stock to buy now? Evotec, Nel, and Lahontan Gold in focus - news.financial
Evotec (EVO) Stock Price, News & Analysis $EVO - MarketBeat
Evotec SE Stock (DE0005664809): Short Interest Eases While Shares Trade Near Lows - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Nigeria
Evotec SE stock (DE0005664809): After CEO exit and audit delay, investors watch turnaround plans - AD HOC NEWS
EVO - Finviz
Evotec ADR Slides 4.3% as Selling Pressure Tests Key Support LevelsQuality Factor - The Legal Advocate
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus! - news.financial
BUY RECOMMENDATIONS for RENK and Desert Gold! SHOCK for Evotec! - news.financial
Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion - AD HOC NEWS
Evotec AG Earnings Call Balances Pain With Promise - The Globe and Mail
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):